{"success":true,"data":{"pressRelease":{"id":"37229","rtpr_id":"nNFC94nBP6","ticker":"IMMP","exchange":"NASDAQ","all_tickers":["IMMP","IMM"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","published_at":"2026-05-17T16:00:13.478Z","article_body":"New York, New York--(Newsfile Corp. - May 17, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Immutep Limited (NASDAQ:\nIMMP) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Immutep securities between March\n24, 2025 and March 12, 2026, both dates inclusive (the \"Class Period\"). Such\ninvestors are encouraged to join this case by visiting the firm's site:\nbgandg.com/IMMP (https://api.newsfilecorp.com/redirect/JkE7ps7wv7).\n\nImmutep Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n1. Defendants concealed and misrepresented the status and prospects of the\nCompany's TACTI-004 trial by relying on prior positive efficacy and safety\nreadouts of efti in other studies, including TACTI-002 and INSIGHT-003, to\nsuggest continued success;\n2. Defendants' statements regarding the TACTI-004 trial's \"strong operational\nprogress\" and the anticipated timing of its interim futility analysis lacked a\nreasonable basis given then-existing clinical data;\n3. based on their access to internal clinical data, analyses, and reports,\nDefendants knew or recklessly disregarded that the risk of the TACTI-004 trial\nfailing to meet its primary efficacy and/or safety endpoints had materially\nincreased; and\n4. as a result, Defendants' statements about the Company's business,\noperations, and prospects were materially false and misleading at all relevant\ntimes.\nWhat's Next for Immutep Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/IMMP\n(https://api.newsfilecorp.com/redirect/GzEgPh08zy), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Immutep you\nhave until July 6, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Immutep Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Immutep Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/mjJ2yHxL1M), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/kXjpycYXE4), X\n(https://api.newsfilecorp.com/redirect/B5EZBUPqQD), Facebook\n(https://api.newsfilecorp.com/redirect/5W8nXTWxbE), or Instagram\n(https://api.newsfilecorp.com/redirect/Lqyk0IG2M5).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296237","article_body_html":"","raw_payload":{"data":{"id":"nNFC94nBP6","title":"Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","ticker":"IMMP","created":"2026-05-17T16:00:13.478Z","tickers":["IMMP","IMM"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - May 17, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Immutep Limited (NASDAQ:\nIMMP) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Immutep securities between March\n24, 2025 and March 12, 2026, both dates inclusive (the \"Class Period\"). Such\ninvestors are encouraged to join this case by visiting the firm's site:\nbgandg.com/IMMP (https://api.newsfilecorp.com/redirect/JkE7ps7wv7).\n\nImmutep Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n1. Defendants concealed and misrepresented the status and prospects of the\nCompany's TACTI-004 trial by relying on prior positive efficacy and safety\nreadouts of efti in other studies, including TACTI-002 and INSIGHT-003, to\nsuggest continued success;\n2. Defendants' statements regarding the TACTI-004 trial's \"strong operational\nprogress\" and the anticipated timing of its interim futility analysis lacked a\nreasonable basis given then-existing clinical data;\n3. based on their access to internal clinical data, analyses, and reports,\nDefendants knew or recklessly disregarded that the risk of the TACTI-004 trial\nfailing to meet its primary efficacy and/or safety endpoints had materially\nincreased; and\n4. as a result, Defendants' statements about the Company's business,\noperations, and prospects were materially false and misleading at all relevant\ntimes.\nWhat's Next for Immutep Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/IMMP\n(https://api.newsfilecorp.com/redirect/GzEgPh08zy), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Immutep you\nhave until July 6, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Immutep Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Immutep Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/mjJ2yHxL1M), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/kXjpycYXE4), X\n(https://api.newsfilecorp.com/redirect/B5EZBUPqQD), Facebook\n(https://api.newsfilecorp.com/redirect/5W8nXTWxbE), or Instagram\n(https://api.newsfilecorp.com/redirect/Lqyk0IG2M5).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296237"},"type":"article","timestamp":"2026-05-17T16:00:13.519542701Z","server_sent_at_ms":1779033613519},"received_at":"2026-05-17T16:00:13.601Z","source_url":"https://www.newsfilecorp.com/release/296237"},"analysis":{"id":"26673","press_release_id":"37229","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman LLC announced a class action lawsuit filed against Immutep Limited and certain officers.\n\nThe complaint alleges materially false statements regarding the TACTI-004 trial for efti, claiming the company concealed increased risks of failure.\n\nInvestors who purchased shares between March 24, 2025, and March 12, 2026, are solicited to join the case or seek lead plaintiff status by July 6, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"}],"products":["TACTI-004","efti","TACTI-002","INSIGHT-003"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman LLC. The release is marketing for the firm, not an issuer disclosure. No certified class or settlement announced."},"tickerRelevance":{"others":[],"primary":"IMMP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman LLC announced a class action lawsuit filed against Immutep Limited and certain officers.\n\nThe complaint alleges materially false statements regarding the TACTI-004 trial for efti, claiming the company concealed increased risks of failure.\n\nInvestors who purchased shares between March 24, 2025, and March 12, 2026, are solicited to join the case or seek lead plaintiff status by July 6, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"}],"products":["TACTI-004","efti","TACTI-002","INSIGHT-003"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-17T16:01:51.154Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":21293,"modelName":"george-droid-qwen-72b"}}